NEW YORK (GenomeWeb News) — DeCode Genetics today said first-quarter revenues decreased 15 percent as R&D spending dropped 18 percent and losses rose 9 percent.
 
Total receipts for the three months ended March 31 fell to $8.6 million from $10.1 million year over year.
 
DeCode said it also had $11.6 million in deferred revenue at the close of the first quarter, which it will recognize over future periods.
 
R&D spending fell to $12.7 million from $15.5 million year over year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.